Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | GAA | P10253 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | BRAF | P15056 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.38 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.37 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.37 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.37 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12391894 | 0.83 | ALDH1A1 (0.43) | KMT2AMEN1SMN1; SMN2L3MBTL1ALDH1A1 | |
| SCHEMBL28768690 | 0.83 | ALDH1A1 (0.47) | KMT2AGAAMEN1SMN1; SMN2L3MBTL1 | |
| SCHEMBL19777750 | 0.80 | NPC1 (0.43) | KMT2AGAAMEN1SMN1; SMN2L3MBTL1 | |
| SCHEMBL7677183 | 0.80 | ALDH1A1 (0.56) | KMT2AGAAMEN1SMN1; SMN2L3MBTL1 | |
| SCHEMBL12427995 | 0.79 | L3MBTL1 (0.42) | KMT2AGAAMEN1SMN1; SMN2L3MBTL1 | |
| SCHEMBL12144349 | 0.77 | CYP1A2 (0.37) | KMT2AGAAMEN1L3MBTL1ALDH1A1 | |
| SCHEMBL7874865 | 0.76 | SMN1; SMN2 (0.39) | KMT2AGAAMEN1SMN1; SMN2L3MBTL1 | |
| SCHEMBL6685160 | 0.76 | ALDH1A1 (0.60) | KMT2AGAAMEN1SMN1; SMN2L3MBTL1 | |
| SCHEMBL4093917 | 0.76 | VCAM1 (0.45) | KMT2AGAAMEN1SMN1; SMN2L3MBTL1 | |
| SCHEMBL29444506 | 0.75 | ALDH1A1 (0.60) | KMT2AMEN1SMN1; SMN2ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12006294-B2 | Therapeutic compounds | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2024-06-11 | — | — | US | disclosed |
| US-20190330157-A1 | THERAPEUTIC COMPOUNDS | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2019-10-31 | — | — | US | disclosed |
| US-20190330157-A1 | THERAPEUTIC COMPOUNDS | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2019-10-31 | — | — | US | disclosed |
| US-9802955-B2 | Tricyclic compounds having antimitotic and/or antitumor activity and methods of use thereof | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2017-10-31 | — | — | US | disclosed |
| US-20170246170-A1 | Tricyclic Compounds Having Antimitotic and/or Antitumor Activity and Methods of Use Thereof | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT | 2017-08-31 | — | — | US | disclosed |
| US-9556198-B2 | Tricyclic compounds having antimitotic and/or antitumor activity and methods of use thereof | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2017-01-31 | — | — | US | disclosed |
| US-20170022217-A1 | Tricyclic Compounds Having Antimitotic and/or Antitumor Activity and Methods of Use Thereof | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT | 2017-01-26 | — | — | US | disclosed |
| US-20160355520-A1 | Tricyclic Compounds Having Cytostatic and/or Cytotoxic Activity and Methods of Use Thereof | DUQUESNE UNIVERSITY OF THE HOLY GHOST | 2016-12-08 | — | — | US | disclosed |
| US-9458167-B2 | Tricyclic compounds having antimitotic and/or antitumor activity and methods of use thereof | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2016-10-04 | — | — | US | disclosed |
| US-20150252053-A1 | Tricyclic Compounds Having Antimitotic and/or Antitumor Activity and Methods of Use Thereof | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT | 2015-09-10 | — | — | US | disclosed |
| US-9056869-B2 | Tricyclic compounds having antimitotic and/or antitumor activity and methods of use thereof | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2015-06-16 | — | — | US | disclosed |
| US-9045489-B2 | Tricyclic compounds having antimitotic and/or antitumor activity and methods of use thereof | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2015-06-02 | — | — | US | disclosed |
| US-8871776-B2 | Tricyclic compounds having cytostatic and/or cytotoxic activity and methods of use thereof | DUQUESNE UNIVERSITY OF THE HOLY GHOST (US) | 2014-10-28 | — | — | US | disclosed |
| US-20130102623-A1 | Tricyclic Compounds Having Cytostatic and/or Cytotoxic Activity and Methods of Use Thereof | DUQUESNE UNIVERSITY OF THE HOLY GHOST | 2013-04-25 | — | — | US | disclosed |
| US-20130096146-A1 | Tricyclic Compounds Having Antimitotic and/or Antitumor Activity and Methods of Use Thereof | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT | 2013-04-18 | — | — | US | disclosed |
| US-8314114-B2 | Tricyclic compounds having cytostatic and/or cytoxic activity and methods of use thereof | DUQUESNE UNIVERSITY OF THE HOLY GHOST (US) | 2012-11-20 | — | — | US | disclosed |
| US-20110295002-A1 | TRICYCLIC COMPOUNDS HAVING ANTIMITOTIC AND/OR ANTITUMOR ACTIVITY AND METHODS OF USE THEREOF | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT | 2011-12-01 | — | — | US | disclosed |
| US-20110207757-A1 | Tricyclic Compounds Having Cytostatic and/or Cytoxic Activity and Methods of Use Thereof | DUQUESNE UNIVERSITY OF THE HOLY GHOST (US) | 2011-08-25 | — | — | US | disclosed |
| US-7960400-B2 | Tricyclic compounds having cytostatic and/or cytotoxic activity and methods of use thereof | DUQUESNE UNIVERSITY OF THE HOLY GHOST (US) | 2011-06-14 | — | — | US | disclosed |
| US-20090062318-A1 | TRICYCLIC COMPOUNDS HAVING CYTOSTATIC AND/OR CYTOTOXIC ACTIVITY AND METHODS OF USE THEREOF | DUQUESNE UNIVERSITY OF THE HOLY GHOST | 2009-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190330157-A1 | THERAPEUTIC COMPOUNDS | OPRL1, INA, OGFR | KMT2A 3083/4885GAA 2851/4885MEN1 4058/4885 |
| US-20090062318-A1 | TRICYCLIC COMPOUNDS HAVING CYTOSTATIC AND/OR CYTOTOXIC ACTIVITY AND METHODS OF USE THEREOF | DHFR, TK1, TYMS | KMT2A 2704/4885GAA 239/4885MEN1 3845/4885 |
| US-20150252053-A1 | Tricyclic Compounds Having Antimitotic and/or Antitumor Activity and Methods of Use Thereof | ABCG2, ABCC1, ABCB1 | KMT2A 3240/4885GAA 276/4885MEN1 2363/4885 |
| US-20130096146-A1 | Tricyclic Compounds Having Antimitotic and/or Antitumor Activity and Methods of Use Thereof | ABCG2, ABCC1, ABCB1 | KMT2A 3240/4885GAA 276/4885MEN1 2363/4885 |
| US-20170022217-A1 | Tricyclic Compounds Having Antimitotic and/or Antitumor Activity and Methods of Use Thereof | ABCG2, ABCC1, ABCB1 | KMT2A 3240/4885GAA 276/4885MEN1 2363/4885 |
| US-12006294-B2 | Therapeutic compounds | OPRL1, INA, OGFR | KMT2A 3083/4885GAA 2851/4885MEN1 4058/4885 |
| US-20160355520-A1 | Tricyclic Compounds Having Cytostatic and/or Cytotoxic Activity and Methods of Use Thereof | DHFR, TK1, TYMS | KMT2A 2704/4885GAA 239/4885MEN1 3845/4885 |
| US-20130102623-A1 | Tricyclic Compounds Having Cytostatic and/or Cytotoxic Activity and Methods of Use Thereof | DHFR, TK1, TYMS | KMT2A 2704/4885GAA 239/4885MEN1 3845/4885 |
| US-20110295002-A1 | TRICYCLIC COMPOUNDS HAVING ANTIMITOTIC AND/OR ANTITUMOR ACTIVITY AND METHODS OF USE THEREOF | ABCG2, ABCC1, ABCB1 | KMT2A 3240/4885GAA 276/4885MEN1 2363/4885 |
| US-20170246170-A1 | Tricyclic Compounds Having Antimitotic and/or Antitumor Activity and Methods of Use Thereof | ABCC1, ABCG2, TP53 | KMT2A 3243/4885GAA 373/4885MEN1 2228/4885 |
| US-20110207757-A1 | Tricyclic Compounds Having Cytostatic and/or Cytoxic Activity and Methods of Use Thereof | DHFR, TK1, TK2 | KMT2A 3111/4885GAA 228/4885MEN1 4135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.